Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)

Launched by THE CLEVELAND CLINIC · Feb 24, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on improving the detection of Primary Aldosteronism (PA), a condition that can cause high blood pressure and may lead to serious health issues if not treated. PA is often caused by an imbalance in certain hormones, and it can sometimes be treated successfully with surgery or specific medications. The study aims to use a test called the Aldosterone Renin Ratio (ARR) to identify more people who might have this condition, which is the most common cause of secondary hypertension, meaning high blood pressure that comes from another health issue.

To participate in this trial, individuals must be between the ages of 18 and 65 and have been diagnosed with essential hypertension, which means their high blood pressure does not have a clear, secondary cause. They should have been diagnosed on at least two occasions in the last six months, even if they are not currently taking blood pressure medications. However, people who are already being treated for PA or have certain other health conditions, like heart failure or kidney problems, cannot participate. Participants will undergo testing and monitoring but can expect to receive guidance and support throughout the process. This study is currently recruiting participants, and it welcomes individuals of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Consent to participate in the study
• • Participants limited to subjects in the CCF
• • Age between and inclusive of 18 and 65 years of age
• • No gender exclusion
• • Patients diagnosed with Essential Hypertension by ICD-10 code on at least two occasions in the previous six months, even if not on medications for hypertension
• • Patients on a single anti-hypertensive medication for at least six months with the diagnosis of hypertension
• Exclusion Criteria:
• • Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)
• • Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism
• • Those with a diagnosis of secondary hyperaldosteronism
• • Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.
• • Pregnancy status (verbal)